900506
Sodium bicarbonate
anhydrous, free-flowing, Redi-Dri™, ReagentPlus®, ≥99.5%
Synonym(s):
Sodium hydrogen carbonate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
NaHCO3
CAS Number:
Molecular Weight:
84.01
UNSPSC Code:
12352302
NACRES:
NA.21
PubChem Substance ID:
EC Number:
205-633-8
Beilstein/REAXYS Number:
4153970
MDL number:
Assay:
≥99.5%
Grade:
anhydrous
Form:
powder
grade
anhydrous
Quality Level
agency
suitable for EPA 300
product line
ReagentPlus®, Redi-Dri™
assay
≥99.5%
form
powder
quality
free-flowing
pKa (25 °C)
(1) 6.37, (2) 10.25 (carbonic acid)
density
2.16 g/mL at 25 °C (lit.)
SMILES string
[Na+].OC([O-])=O
InChI
1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
InChI key
UIIMBOGNXHQVGW-UHFFFAOYSA-M
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Redi-Dri is a trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under Sodium bicarbonate
Storage Class
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Eric A J Hoste et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25(3), 747-758 (2009-08-26)
There have been conflicting reports on the use of intravenous administration of sodium bicarbonate for prevention of contrast-induced acute kidney injury (CI-AKI). The aim of this study was to evaluate the use of sodium bicarbonate for prevention of CI-AKI. This
Sophia Zoungas et al.
Annals of internal medicine, 151(9), 631-638 (2009-11-04)
Intravenous sodium bicarbonate has been proposed to reduce the risk for contrast-induced nephropathy (CIN). To determine the effect of sodium bicarbonate on the risk for CIN. MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from 1950 to
Kate M Hatzopoulos et al.
Investigative ophthalmology & visual science, 55(6), 3957-3970 (2014-06-05)
Retinal angiogenesis, neural dysfunction, and microglial activation occur in both humans with retinopathy of prematurity and in animal models of the disease. The aim of this study was to assess whether blockade of the renin-angiotensin system ameliorated these effects in